Starting at Discovery

Hear Vivek Ramaswamy describe how Roivant is leveraging the scale of the pharmaceutical industry, and the mentality of a start-up, to help bring new and powerful medicines to market.

Audio Transcript

00:00:07 —

Vivek Ramaswamy

We’re culturally wired a little bit differently to most Pharma companies in that we don’t discover most of our drugs in-house. Rather, we view the entire world as our laboratory – because the real problem as we see it isn’t in the discovery of drugs – that’s happening in an inspiring way. The real problem is taking those discoveries, and translating them into becoming approved medicines that can actually reach patients and impact their lives. And to that end – the process is broken.

00:00:40 —


How are you different to other pharmaceutical companies?

00:00:42 —

Vivek Ramaswamy

What we’re trying to do is to borrow from the best of large scale Pharmaceutical companies, and some of the benefits of scale, but to pair that with the benefits of entrepreneurship, of small, scrappy nimble startups.

00:00:53 —

Vivek Ramaswamy

We build these things called Vants. Effectively, nimble, entrepreneurial, biotech or health tech companies in their own right, with their own leadership teams, their own operating teams that work on specific projects that advance say, a given medicine to patients.

00:01:10 —

Vivek Ramaswamy

We can work with any partner, any individual academic University, company start-up around the world to help them advance their project by using Roivant’s platform to take an existing discovery through development.

00:01:25 —


How do you see the industry changing in the near future?

00:01:28 —

Vivek Ramaswamy

Historically, the pharma industry’s model has been to deliver chronic therapies, drugs that you take once or twice or thrice a day, over the course of your lifetime.

00:01:36 —

Vivek Ramaswamy

Because of fundamental changes in science and genetic medicine, we’re going to see more one time therapies and even cures.

00:01:44 —

Vivek Ramaswamy

As a consequence, I think we’re going to see more and more pharma companies, really thinking about problems beyond just developing individual medicines, and moving on to the healthcare of the patient more holistically.

00:01:53 —

Vivek Ramaswamy

We couldn’t have imagined cures of the kinds that we can deliver with new gene therapies, with new RNA based medicines. Now it’s possible.

00:02:03 —

Vivek Ramaswamy

And I think we have to really think about a new narrative for what life itself looks like in a world where people are living longer.

Next Insight

What Makes a Great Product Market Leader?

In this episode of CNBC’s The Playbook, Deep Nishar shares what it takes to be a great product leader based on his successes and failures in product development at LinkedIn and Google.

Scroll To Close